Hygieia, a Livonia, MI-based digital health company, raised $17M in Series B funding.
The round was led by Firstime Ventures with participation from existing investors.
The company intends to use the funds to expand partnerships with endocrinology practices and access to its d-Nav® insulin dose automation technology for people with type 2 diabetes.
Led by Eran Bashan, Ph.D., CEO, Hygieia provides an insulin therapy and maker of the d-Nav® Insulin Management Program. The d-Nav program includes an AI-powered application that helps people with type 2 diabetes use insulin in a safe and effective way to control their blood sugar levels. The program was developed by two University of Michigan researchers and has been peer-reviewed with studies published in leading medical journals. Studies show that nearly 90 percent of people using d-Nav achieve lower A1c within three months.
Hygieia expects to have endocrinology partnerships in 10 states over the next two years. Currently, the company has two international licenses, in Northern Ireland and in Israel. Clalit, the largest integrated health system in Israel, is launching a pilot program with Hygieia this month.